Novelion Therapeutics Inc. (NVLN) Forms $3.68 Double Bottom; Avinger (AVGR) Shorts Up By 12.02%

Avinger, Inc. (NASDAQ:AVGR) Logo

Novelion Therapeutics Inc. (NVLN) formed double bottom with $3.39 target or 8.00% below today’s $3.68 share price. Novelion Therapeutics Inc. (NVLN) has $68.83 million valuation. The stock increased 1.94% or $0.07 during the last trading session, reaching $3.68. About 34,143 shares traded. Novelion Therapeutics Inc. (NASDAQ:NVLN) has declined 55.52% since June 30, 2017 and is downtrending. It has underperformed by 68.09% the S&P500. Some Historical NVLN News: 15/03/2018 – Novelion Therapeutics 4Q Loss $24.6M; 15/03/2018 – Novelion Therapeutics 4Q Loss/Shr $1.32; 10/05/2018 – NOVELION THERAPEUTICS INC QUARTERLY NET LOSS PER SHARE $1.76; 15/03/2018 – NOVELION THERAPEUTICS SAYS THE FINANCING FACILITY PROVIDES FOR A $20 MLN TERM LOAN TO CO’S UNIT AEGERION PHARMACEUTICALS; 31/03/2018 – Novelion Therapeutics Supports World Lipodystrophy Day; 10/05/2018 – Novelion Therapeutics 1Q Loss/Shr $1.76; 15/03/2018 – NOVELION – AEGERION’S OBLIGATIONS UNDER FACILITY ARE SECURED BY SUBSTANTIALLY ALL OF ITS ASSETS, INCLUDING IP RIGHTS OF MYALEPT AND JUXTAPID; 10/05/2018 – Novelion Therapeutics 1Q Rev $27.5M; 15/03/2018 – NOVELION UNIT IN $20M TERM LOAN PACT WITH SARISSA & BROADFIN; 15/03/2018 – NOVELION THERAPEUTICS SAYS AEGERION PLANS TO USE THE CAPITAL TO SUPPORT ONGOING DEVELOPMENT OF METRELEPTIN IN ADDITIONAL INDICATIONS

Avinger Inc (NASDAQ:AVGR) had an increase of 12.02% in short interest. AVGR’s SI was 353,300 shares in June as released by FINRA. Its up 12.02% from 315,400 shares previously. With 2.64 million avg volume, 0 days are for Avinger Inc (NASDAQ:AVGR)’s short sellers to cover AVGR’s short positions. The stock decreased 5.65% or $0.1 during the last trading session, reaching $1.67. About 338,063 shares traded. Avinger, Inc. (NASDAQ:AVGR) has declined 86.02% since June 30, 2017 and is downtrending. It has underperformed by 98.59% the S&P500.

Avinger, Inc., a commercial-stage medical device company, designs, makes, and sells image-guided and catheter systems used by physicians to treat patients with peripheral arterial disease in the United States and Europe. The company has market cap of $9.29 million. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. It currently has negative earnings. The companyÂ’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

More recent Avinger, Inc. (NASDAQ:AVGR) news were published by: Globenewswire.com which released: “Avinger Appoints Mark Weinswig as Chief Financial Officer” on June 13, 2018. Also Nasdaq.com published the news titled: “Avinger Announces Successful Treatment of First Patients with Next-Generation Pantheris in Several Centers …” on June 26, 2018. Nasdaq.com‘s news article titled: “Avinger’s Ocelot Technology Featured in Live Case Transmission at Complex Cardiovascular Catheter Therapeutics …” with publication date: June 21, 2018 was also an interesting one.